Radioligand Therapy 177Lu-PSMA-617 in Patients With Progressive PSMA-positive mCRPC
Evan Y. Yu, MD, reviews the use of LuPSMA radioligand therapy and the role of precision medicine in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.